Profile data is unavailable for this security.
About the company
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
- Revenue in JPY (TTM)804.39bn
- Net income in JPY49.37bn
- Incorporated1941
- Employees13.51k
- LocationEisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
- Phone+81 338173030
- Fax+81 338113305
- Websitehttps://www.eisai.co.jp/index.html
More ▼
Mergers & acquisitions
| Acquired company | 4523:TYO since announced | Transaction value |
|---|---|---|
| EcoNaviSta Inc | 5.29% | 108.23m |
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sawai Group Holdings Co Ltd | 200.00bn | 309.00m | 272.84bn | 3.31k | 3,714.56 | 1.54 | 17.14 | 1.36 | 0.636 | -11.40 | 1,703.92 | 1,531.41 | 0.5559 | 1.24 | 4.09 | 60,422,060.00 | 0.0862 | -0.2327 | 0.1143 | -0.3187 | 29.39 | 32.95 | 0.155 | -0.475 | 0.812 | 0.7435 | 0.3737 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
| Tsumura & Co | 189.50bn | 29.01bn | 322.08bn | 4.27k | 10.84 | 1.02 | 7.55 | 1.70 | 387.15 | 387.15 | 2,524.84 | 4,095.99 | 0.374 | 0.7106 | 2.41 | 44,357,680.00 | 6.01 | 5.53 | 8.06 | 6.85 | 47.60 | 49.39 | 16.06 | 14.50 | 1.45 | -- | 0.2856 | 31.65 | 20.05 | 8.00 | 94.10 | 18.69 | 23.07 | 16.27 |
| Nippon Shinyaku Co Ltd | 160.55bn | 31.95bn | 354.21bn | 2.24k | 10.63 | 1.31 | 9.28 | 2.21 | 474.28 | 474.28 | 2,383.64 | 3,855.98 | 0.5677 | 1.14 | 3.73 | 71,576,900.00 | 11.30 | 10.89 | 12.62 | 12.74 | 67.91 | 63.93 | 19.90 | 17.67 | 3.79 | -- | 0.0096 | 30.58 | 8.08 | 6.56 | 25.94 | 14.06 | 80.48 | 7.59 |
| Hisamitsu Pharmaceutical Co Inc | 159.27bn | 19.99bn | 481.06bn | 2.80k | 23.11 | 1.67 | 17.48 | 3.02 | 276.99 | 276.99 | 2,208.13 | 3,837.32 | 0.4704 | 2.64 | 3.42 | 56,901,390.00 | 6.04 | 4.34 | 7.25 | 4.99 | 59.05 | 57.83 | 12.84 | 10.32 | 3.28 | -- | 0.0086 | 50.29 | 10.09 | 2.04 | 55.76 | 3.08 | 29.89 | 0.7127 |
| Santen Pharmaceutical Co Ltd | 287.99bn | 30.60bn | 553.99bn | 3.85k | 18.68 | 1.95 | 11.37 | 1.92 | 92.03 | 92.03 | 865.27 | 880.97 | 0.7205 | 2.26 | 4.18 | 74,823,070.00 | 7.63 | 3.94 | 9.43 | 4.93 | 56.89 | 58.97 | 10.59 | 6.01 | 1.89 | -- | 0.1757 | 71.86 | -0.6494 | 4.43 | 36.09 | 8.94 | 3.61 | 5.92 |
| Rohto Pharmaceutical Co Ltd | 333.80bn | 35.74bn | 605.56bn | 9.14k | 16.48 | 2.11 | 11.49 | 1.81 | 155.55 | 155.55 | 1,450.25 | 1,217.84 | 0.7871 | 2.34 | 4.76 | 36,504,810.00 | 8.47 | 8.59 | 11.85 | 11.70 | 56.21 | 57.78 | 10.76 | 10.57 | 1.56 | -- | 0.1387 | 21.12 | 13.95 | 10.38 | 0.2263 | 15.01 | 10.42 | 22.59 |
| Sumitomo Pharma Co Ltd | 453.40bn | 110.09bn | 887.12bn | 3.83k | 8.05 | 3.07 | 6.74 | 1.96 | 277.11 | 277.11 | 1,141.22 | 727.28 | 0.5438 | 1.95 | 3.99 | 118,318,100.00 | 13.20 | -5.49 | 23.02 | -8.49 | 59.24 | 67.88 | 24.28 | -13.24 | 1.01 | 4.17 | 0.4726 | -- | 26.79 | -3.75 | 107.50 | -10.32 | -0.4856 | -- |
| Ono Pharmaceutical Co Ltd | 509.35bn | 62.40bn | 1.24tn | 4.29k | 18.71 | 1.39 | 12.47 | 2.43 | 132.76 | 132.76 | 1,084.01 | 1,786.88 | 0.4702 | 2.14 | 3.38 | 118,811,500.00 | 5.77 | 10.78 | 6.61 | 12.37 | 69.79 | 73.23 | 12.27 | 21.23 | 2.56 | 125.26 | 0.1283 | 36.33 | -3.14 | 10.73 | -60.89 | -3.47 | -18.66 | 12.20 |
| Kyowa Kirin Co Ltd | 482.21bn | 36.57bn | 1.26tn | 5.67k | 34.40 | 1.49 | 20.60 | 2.62 | 69.85 | 69.85 | 920.95 | 1,616.31 | 0.455 | 1.78 | 3.30 | 85,061,030.00 | 3.45 | 6.37 | 4.11 | 7.25 | 73.32 | 75.13 | 7.58 | 14.65 | 2.27 | 11.63 | 0.00 | 46.38 | 12.06 | 10.14 | -26.26 | 9.71 | 37.71 | 6.67 |
| Eisai Co Ltd | 804.39bn | 49.37bn | 1.31tn | 13.51k | 25.61 | 1.48 | 14.49 | 1.63 | 175.04 | 175.04 | 2,852.38 | 3,028.67 | 0.583 | 0.8151 | 3.84 | 59,557,980.00 | 3.69 | 3.81 | 5.07 | 5.14 | 78.29 | 77.47 | 6.32 | 6.44 | 1.47 | -- | 0.212 | 98.01 | 6.42 | 2.56 | 9.49 | -17.54 | -14.48 | 0.00 |
| Shionogi & Co Ltd | 465.35bn | 194.86bn | 3.02tn | 4.96k | 14.82 | 1.91 | 13.99 | 6.49 | 228.94 | 228.94 | 546.70 | 1,779.33 | 0.2869 | 0.8648 | 2.76 | 93,915,640.00 | 11.98 | 12.17 | 13.13 | 13.74 | 84.50 | 84.91 | 41.78 | 38.30 | 5.21 | -- | 0.0148 | 27.87 | 0.7325 | 5.62 | 5.19 | 6.88 | 34.66 | 12.30 |
| Astellas Pharma Inc | 2.06tn | 322.91bn | 4.42tn | 13.64k | 13.59 | 2.48 | 8.58 | 2.14 | 179.57 | 179.57 | 1,145.43 | 984.21 | 0.5841 | 1.27 | 2.90 | 151,038,200.00 | 9.15 | 3.05 | 14.11 | 4.45 | 81.00 | 81.15 | 15.67 | 5.42 | 0.839 | 41.32 | 0.2913 | 131.42 | 19.25 | 8.01 | 197.72 | -23.64 | -5.94 | 13.09 |
| Otsuka Holdings Co Ltd | 2.42tn | 449.11bn | 5.07tn | 35.34k | 11.09 | 1.73 | 8.98 | 2.10 | 842.65 | 842.65 | 4,540.85 | 5,413.66 | 0.64 | 2.11 | 4.86 | 68,439,860.00 | 12.01 | 5.91 | 15.12 | 7.27 | 71.72 | 69.18 | 18.76 | 9.89 | 1.65 | -- | 0.0695 | 32.93 | 15.42 | 10.78 | 182.13 | 21.96 | 15.32 | 3.71 |
Data as of Feb 06 2026. Currency figures normalised to Eisai Co Ltd's reporting currency: Japanese Yen JPY
31.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 18.68m | 6.41% |
| Wellington Management Co. LLPas of 30 May 2025 | 14.04m | 4.82% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 9.85m | 3.38% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Sep 2025 | 9.72m | 3.33% |
| Amova Asset Management Co., Ltd.as of 15 Sep 2025 | 8.85m | 3.04% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 8.45m | 2.90% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 6.20m | 2.13% |
| BlackRock Japan Co. Ltd.as of 31 Oct 2025 | 5.78m | 1.98% |
| BlackRock Fund Advisorsas of 31 Oct 2025 | 5.77m | 1.98% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026 | 4.89m | 1.68% |
More ▼
Data from 30 Jun 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
